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A B S T R A C T
Purpose: To evaluate the efﬁcacy of ruﬁnamide as an add-on treatment in children and adolescents with
Lennox-Gastaut syndrome (LGS).
Methods: The study was an open-label, observational clinical trial of ruﬁnamide as an add-on treatment
in intractable LGS patients. This intent-to-treat trial included 4 weeks of scheduled titrated doses and a
12-week maintenance phase with a target dose of 20–40 mg/kg ruﬁnamide, adjusted according to its
effectiveness and tolerability after a baseline period of 4 weeks. The primary outcome was measured by
the seizure-reduction rate according to individual seizure type over the 12-week maintenance period.
Results: One hundred and twenty-eight patients with LGS who were determined to be unresponsive to
one or more antiepileptic drugs or dietary therapy were enrolled. Of the 128 patients enrolled, 112
(87.5%) completed the study. After add-on ruﬁnamide treatment, 46 patients (35.9%) achieved a more
than 50% reduction in seizure frequency and 10 (7.8%) patients became seizure-free. When we identiﬁed
those who responded with an at least 50% reduction in seizure frequency, 39.4% of the responders
reported reductions in convulsive seizures, 36.4% in drop attacks, 33.3% in myoclonic seizures, and 20.0%
in epileptic spasms. Overall, 32.8% of patients reported adverse effects, which were mostly mild and
transient in nature. The most common adverse effects were fatigue (15 patients, 11.7%) and poor
appetite (9 patients, 7.0%). Twenty-one (16.4%) patients experienced an increased seizure frequency.
Conclusions: Ruﬁnamide appears to be a safe and effective adjuvant treatment for many cases of
intractable LGS.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Lennox-Gastaut syndrome (LGS) is a medically intractable
epilepsy syndrome characterized by various types of seizures,
generalized slow spike and wave discharges and paroxysmal fast
activity on electroencephalograms (EEG), and psychomotor
retardation.1,2 Seizures in LGS patients are usually refractory to
multiple antiepileptic treatments, and patients suffer from
frequent disabling seizures and adverse effects from polypharma-
ceutical treatment. The practical goal of treating LGS patients is to
reduce the seizure frequency and to prevent seizure-related
physical trauma.
The efﬁcacy of some antiepileptic drugs (AEDs) such as
lamotrigine, felbamate, and topiramate as adjuvant therapies to* Corresponding author at: Division of Pediatric Neurology, Pediatric Epilepsy
Clinics, Severance Children’s Hospital, Epilepsy Research Institute, Yonsei
University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752,
Republic of Korea. Tel.: +82 2 2228 2061; fax: +82 2 393 9118.
E-mail address: hdkimmd@yuhs.ac (H.D. Kim).
d These authors contributed equally to this work.
1059-1311/$ – see front matter  2012 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2012.02.006reduce the seizure frequency in LGS patients has been proven.3–5
However, these AEDs have limitations in that they control only
some types of seizures. No novel drug has effectively controlled all
types of seizures in LGS patients.6,7
Ruﬁnamide is a triazole derivative that is structurally distinct
from other antiepileptic agents. Randomized controlled trials have
proven the efﬁcacy and safety of adjuvant ruﬁnamide therapy over
a placebo in LGS patients.8,9 In this study, we evaluated the efﬁcacy
of ruﬁnamide as an adjuvant treatment according to different
seizure types in children with LGS.
2. Patients and methods
2.1. Subjects
Children and adolescents younger than 20 years of age were
eligible for the study if they had been diagnosed with LGS and had
experienced four or more convulsive seizures and several other
types of seizures in the previous month. LGS was diagnosed when
the patient had an EEG pattern typical of LGS, which includes
generalized slow sharp and wave discharges and generalizedvier Ltd. All rights reserved.
Fig. 1. (A) Trial design. (B) Trial progression.
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such as convulsive (tonic, clonic, and tonic–clonic), drop attack
(tonic–atonic or atonic seizure), myoclonic, epileptic spasms, or
atypical absence, conﬁrmed by a routine EEG or video EEG
monitoring including non-rapid eye movement sleep within the
most recent six months. Patients were excluded if there was
evidence of a progressive cerebral lesion or neurodegenerative
metabolic disorder, or if the patients experienced less than four
pre-existing convulsive seizures in the one-month baseline period.
During the evaluation period, patients who were treated with
other AEDs, except for short-acting intravenous benzodiazepine
for rescue from prolonged seizures, were also excluded.
All of the patients were ﬁrst divided into a cryptogenic group
and a symptomatic group. Patients who had developed neurologic
dysfunction before seizure onset and showed any abnormalities on
neuroimaging or dysmorphic features through an extensive
genetic and metabolic work-up were assigned to the symptomatic
group. The symptomatic group was again sub-classiﬁed, according
to the cause of LGS, into four groups, ‘‘malformation of cortical
development,’’ ‘‘destructive encephalopathy,’’ ‘‘metabolic causes,’’
and ‘‘unknown etiology.’’ Metabolic causes were assigned only to
those patients with a diagnosis conﬁrmed through speciﬁc
biochemical or pathological methods. Among the symptomatic
groups, those who had no speciﬁc abnormal features based on
extensive etiological evaluation were assigned to the unknown
etiology group. In comparison to the symptomatic group, the
cryptogenic group included patients with no abnormal neurologi-
cal signs or preceding developmental delay before seizure onset,
who were clearly distinct from the unknown etiology group due to
the absence of any abnormal structural or biochemical features
based on neuroimaging, genetic, and metabolic evaluations.
The study was conducted at two referral hospitals offering
pediatric epilepsy care. The protocol was approved by the
institutional review boards of both study centers. Informed
consent was obtained from all participants and their guardians.
2.2. Study design
This intent-to-treat study was an open-label, observational
clinical trial of ruﬁnamide as an add-on treatment in intractable
LGS patients with no allocation of patients to a placebo group. A
prospective baseline phase of one month was used to assess
seizure frequency according to individual seizure type. The 16-
week treatment period included an initial 4 weeks of titration and
12 weeks of maintenance. Following the screening, titration was
started at 10 mg/kg/day and was increased by 5–10 mg/kg every
1–2 weeks to achieve a maintenance dosage of 20–40 mg/kg/day
with a ﬁxed dose escalation. The target dose was modiﬁed
according to the patient’s tolerability and the treatment efﬁcacy
(Fig. 1A).
2.3. Outcome measures
Throughout the trial, patients or their guardians maintained
diaries to record the type and frequency of seizures as well as
possible adverse effects. At each hospital visit, the investigator
reviewed the patient’s seizure diary. Patient visits were scheduled
at 4, 8, 12, and 16 weeks. All efﬁcacy analyses were based on the
intent-to-treat population, who were given ruﬁnamide. Seizures
were classiﬁed into ﬁve groups: convulsive (tonic, clonic, and
tonic–clonic), any type of drop attack, myoclonic, epileptic spasms,
and atypical absence, according to the guidelines of the
International League Against Epilepsy (ILAE).10 A drop attack
was deﬁned as a tonic–atonic or atonic seizure because of the
practical difﬁculties for the parents to differentiate tonic from
tonic–atonic seizures that cause the patients to fall. Seizureoutcome was evaluated based on the reduction in the rate of each
of the ﬁve seizure types that the parents reported most frequently.
Seizure frequency changes were classiﬁed as ‘‘seizure free,’’
‘‘greater than 75% decrease,’’ ‘‘50–75% decrease,’’ ‘‘less than 50%
decrease,’’ ‘‘no change,’’ or ‘‘worsening of seizures,’’ relative to the
baseline values. In patients with atypical absence seizures, the
response was evaluated as ‘‘worthwhile improvement’’ or ‘‘per-
sisting’’ due to the difﬁculty in determining the frequency of the
seizures of this type. The percentage of patients with a more than
50% reduction in seizure frequency was also assessed, and was
deﬁned as the responder rate. We calculated the percentage of
change in seizure frequencies in all patients after a 12-week
treatment with ruﬁnamide compared with the baseline seizure
frequency according to seizure type. The tolerability and safety of
ruﬁnamide were monitored throughout the trial by neurological
and physical examinations that took the patient’s weight, vital
signs, and evaluation of treatment-related adverse effects into
account (one visit during the baseline period and four subsequent
visits during the 12-week trial). Clinical laboratory evaluations
including a complete blood count, aspartate aminotransferase/
alanine aminotransferase assays, and electrocardiography were
performed at the initial phase and at the end of the study. The
incidence of treatment-related adverse events was also assessed.
2.4. Statistical methods
The efﬁcacy parameter of interest was the seizure reduction
rate during the treatment period. The intent-to-treat (ITT)
population for the efﬁcacy analyses included all patients who
received at least one dose of ruﬁnamide and who underwent at
least one efﬁcacy evaluation during treatment. Statistical analysis
of nonparametric measures was conducted using SAS version 9.2
(Statistical Analysis System Institute, Cary, NC, USA). The level of
signiﬁcance was set to P < 0.05.
3. Results
3.1. Subject characteristics
Of the 128 patients with LGS, 85 were boys and 43 were girls
with a mean age of 9.4  4.7 years (1.8–19.9 years). The duration of
Table 2
Seizure reduction rate according to main seizure type.
Convulsive Drop attack Myoclonic Spasms
No. of patients 71 33 9 10
Seizure-free 6 3 0 1
75–100% 14 6 2 0
50–75% 8 3 1 1
<50% 4 4 2 0
No reduction 27 11 3 6
Aggravation 12 6 1 2
% of respondersa 39.4 36.4 33.3 20.0
a Responders were deﬁned as those patients who showed a greater than 50%
reduction in seizure frequency. Responder rates according to seizure type were not
signiﬁcantly different.
The efﬁcacy of ruﬁnamide in patients with absence seizures was classed as
‘‘worthwhile improvement’’ or ‘‘seizure persistence.’’ Twenty percent of patients
(one out of ﬁve) with absence seizures experienced a ‘‘worthwhile improvement’’.
Table 1
Demographic and clinical characteristics of the study population.
Characteristic Values
Gender (male:female) 85:43
Age, mean  SD (range) 9.4  4.7 (1.8–19.9) years
Final effective dose, mean  SD 31.7  8.7 mg/kg/day
Age of seizure onset, mean  SD 28.7  39.0 months
Etiology, n (%)
Cryptogenic etiology 27 (21.1%)
Malformation of cortical development 35 (27.3%)
Destructive encephalopathy 30 (23.4%)
Metabolic cause 2 (1.6%)
Unknown cause 34 (26.6%)
Seizure type, n (%)
Convulsive seizure 71 (55.5%)
Drop attack 33 (25.8%)
Myoclonic seizure 9 (7.0%)
Epileptic spasms 10 (7.8%)
Atypical absence 5 (3.9%)











Incidence of common adverse effects.
Adverse effect n %
Patients with any adverse effects 42 32.8
Fatigue 15 (1)a 11.7




Poor sleep quality 5 3.9
Vomiting 3 (1)a 2.3
Other 6 (2)b 4.6
a One patient discontinued ruﬁnamide due to adverse effects.
b Two patients discontinued ruﬁnamide due to eye blinking and menorrhagia.
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demographic characteristics of the patients are listed in Table 1.
Ruﬁnamide was started at 10 mg/kg/day and titrated weekly with a
5–10 mg/kg increase every 1–2 weeks for 4 weeks. The ﬁnal
maintenance dose was 31.7  8.7 mg/kg/day. At the time of
ruﬁnamide treatment initiation, all patients were receiving an
average of 3.3 (range, 1–6) concomitant AEDs; 18 patients (14.1%)
were on a ketogenic (n = 16) or modiﬁed Atkins diet (n = 2), and three
patients had been implanted with a vagal nerve stimulation device.
The most commonly used concomitant AEDs were valproate (n = 81,
63.3%), lamotrigine (n = 57, 44.5%), benzodiazepines (n = 53, 41.4%),
levetiracetam (n = 51, 39.8%), and zonisamide (n = 50, 39.1%). During
maintenance, all other AEDs, including dietary interventions and
vagal nerve stimulation parameters, were maintained in the same
manner as during the baseline period.
3.2. Efﬁcacy
Among the 128 patients treated with ruﬁnamide, 112 patients
(87.5%) were retained after 12 weeks (Fig. 1B). The causes of
premature discontinuation of ruﬁnamide included inadequate
seizure control in 11 patients (8.6%), adverse effects in 4 patients
(3.1%), and loss to follow-up of 1 patient (0.8%). The overall seizure
reduction rate was 31.7%. Ruﬁnamide reduced the seizure
frequency by 100% (seizure freedom) in 7.8% of patients (n = 10),
more than 75% in 18.0% of patients (n = 23), 50–75% in 10.2% of
patients (n = 13), and by less than 50% in 8.6% of patients (n = 11).
However, 39.1% (n = 50) of patients experienced no change in
seizure frequency, and 16.4% (n = 21) reported a more than 25%
increase in seizure frequency. Patients with a greater than 50%
reduction in seizure frequency were deﬁned as responders. The
clinical efﬁcacy according to seizure type is summarized in Table 2.
The highest responder rate of 39.4% (n = 28) was observed in the
convulsive seizure group, followed by the drop attack group
(36.5%), myoclonic seizure group (33.3%), and epileptic spasm
group (20%). Twenty percent of patients with atypical absence
seizures reported ‘‘worthwhile improvement’’ in seizure frequen-
cy. Among ten patients who became seizure-free after ruﬁnamide
adjuvant treatment, six (60.0%) had convulsive seizures, three haddrop attacks, and only one had epileptic spasms as the main seizure
type. When we analyzed the correlation between efﬁcacy and AED
combination, including the ketogenic diet, we did not detect a
signiﬁcant synergistic effect from ruﬁnamide (t-test, P > 0.05).
3.3. Safety
Adverse effects were reported in 32.8% patients (n = 42).
Proﬁles of adverse effects are shown in Table 3. The most
commonly reported adverse effects were fatigue in 15 patients,
poor appetite in 9 patients, as well as somnolence, rash,
hyperactivity, poor quality of sleep, and vomiting, in order of
frequency. Adverse effects leading to premature discontinuation of
ruﬁnamide were fatigue, vomiting, menorrhagia, and eye blinking,
with each being found in one patient, for a total of four patients
being withdrawn from the study; all of these symptoms resolved
spontaneously after discontinuing treatment. None of the adverse
effects resulted in permanent health problems.
4. Discussion
The results of this study show that ruﬁnamide as an add-on
therapy in pediatric patients with LGS is both effective and safe.
We found that 7.8% (10 of 128 patients) of patients became
seizure-free and 35.9% (46 of 128 patients) experienced a more
than 50% reduction in disabling seizures with ruﬁnamide
medication. The overall seizure reduction rate was 31.7%. This is
consistent with the 32.7% median seizure reduction rate reported
in 74 ruﬁnamide-treated patients in a randomized, controlled,
double-blind trial by Glauser et al.8 and the 41.0% responder rate in
total seizures reported for LGS patients over a period of 12 months
by Kluger et al.9 Among the ﬁve seizure types, patients with
convulsive seizures and drop attacks beneﬁted the most from
ruﬁnamide treatment. Considering that convulsive seizures and
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types (104, 81.3%) within this population, ruﬁnamide is an
effective adjuvant therapy in controlling the seizures that have
the greatest impact on the quality of life for LGS patients. Drop
attacks were the second most common disabling seizure type in
our study group, and the responder rate in this group was 36.4%.
This ﬁnding is comparable to the 42.5% reduction in the frequency
of tonic–atonic seizures (drop attacks), compared to a placebo
group reported by Glauser et al.9 Ruﬁnamide appears to be better
than topiramate at controlling drop attacks; a previous study
reported that only 28% of drop-attack patients were topiramate
responders (n = 13/46).5
There are few reports on the efﬁcacy of ruﬁnamide in patients
with epileptic spasms. Olson et al.11 reported a responder rate of
53% after ruﬁnamide add-on therapy in 38 patients with epileptic
spasms with or without hypsarrhythmia. In this study, we
observed a 20.0% responder rate in ten patients experiencing
epileptic spasms with LGS. The difference in the number of patients
between the two studies could be responsible for such a difference
in the responder rates. Considering that there are very limited
treatment options available for epileptic spasms, ruﬁnamide can
be considered an effective adjuvant treatment based on our
ﬁndings.
There were no signiﬁcant differences in the efﬁcacy of
ruﬁnamide according to seizure etiology. The responder rates
for patients with a malformation of cortical development (MCD) or
cryptogenic etiology were not signiﬁcantly different (P = 0.173),
although ruﬁnamide showed the best efﬁcacy in MCD patients,
with a responder rate of 42.9% for any seizure type. This response
rate is higher than that observed for patients with a cryptogenic
etiology (29.6%), which was regarded as a favorable factor in terms
of the ability to control seizures. Further investigations of longer
duration in a larger population are necessary to validate the
differences we observed in ruﬁnamide efﬁcacy between the
etiological groups.
In our study, ruﬁnamide was well-tolerated and safely
maintained for 12 weeks after titration, with a retention rate of
87.5% (n = 112). Adverse effects were reported in 32.8% of patients,
and all adverse effects were of mild to moderate severity. Frequent
adverse effects were similar to those reported in previous
studies,8,9,12,13 namely fatigue, poor appetite, somnolence, rash,
and hyperactivity. A patient reported menorrhagia during ruﬁna-
mide maintenance for ten weeks, which has not been reported
previously. The relationship between ruﬁnamide and menorrhagia
is not clear. The patient with this AE was a 16-year-old female in
menarche, and no other abnormal causative ﬁndings of menor-
rhagia were revealed through a gynecological evaluation. While
eye blinking has not been reported in previous reports, diplopia
was reported in 19.9% of ruﬁnamide patients, compared to 3.2% of
placebo patients,14 which could represent eye blinking in severely
retarded patients. Ruﬁnamide treatment was discontinued in 8 of
128 (6.2%) patients within 12 weeks due to a worsening of seizure
frequency, and 21 of 128 patients (16.4%) experienced a worsening
of seizure frequency or intensity. This rate is somewhat higher than
the 13% reported in patients with childhood epileptic encephalop-
athy in the study by Coppola et al.15 However, we were not able to
determine the factors related to the development of adverse effects
due to limited study duration and patient number.The results of this study should be considered while keeping in
mind the fact that the study was not double-blinded and lacked a
placebo arm. Moreover, the short duration of the trial cannot
guarantee the long-term results of ruﬁnamide treatment. In
conclusion, ruﬁnamide adjuvant treatment appears to be effective,
safe, and well-tolerated in patients with LGS. Our ﬁndings suggest
that ruﬁnamide can provide a considerable beneﬁt in controlling
various types of seizures in LGS patients.
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